Literature DB >> 26622440

Wogonin inhibits osteoclast differentiation by inhibiting NFATc1 translocation into the nucleus.

Xiaolin Geng1, Libin Yang1, Chao Zhang1, Hua Qin1, Qiudong Liang1.   

Abstract

The aim of the present study was to identify a natural product with the ability to inhibit nuclear factor of activated T cells c1 (NFATc1) translocation from the cytoplasm to the nucleus by high-throughput screening, and to investigate the effect of the natural product upon osteoclast differentiation and its underlying mechanism. An NFATc1 antagonist redistribution assay was performed in U2OS-NFATc1 cells against a natural product library, and Wogonin was found to have the ability to inhibit the NFATc1 translocation from the cytoplasm to the nucleus. The effect of Wogonin on NFATc1 transcription activation was further determined by luciferase assay. An osteoclast differentiation assay was executed to evaluate the effect of Wogonin on osteoclast differentiation. The effect of Wogonin upon the vital genes in osteoclast differentiation was investigated using fluorescent quantitative polymerase chain reaction analysis. The natural product Wogonin significantly inhibited the translocation of NFATc1 from the cytoplasm to the nucleus and its transcriptional activation activity. Wogonin also significantly inhibited osteoclast differentiation and decreased the transcription of osteoclast-associated immunoglobulin-like receptor, tartrate-resistant acid phosphatase and calcitonin receptor. In conclusion, the natural product Wogonin inhibited osteoclast differentiation through the inhibition of NFATc1 translocation from the cytoplasm to the nucleus, and thus the downregulation of genes associated with osteoclast differentiation, which marked Wogonin as a potential treatment for osteoporosis.

Entities:  

Keywords:  NFATc1; Wogonin; osteoclast; osteoporosis

Year:  2015        PMID: 26622440      PMCID: PMC4533208          DOI: 10.3892/etm.2015.2615

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  21 in total

1.  RANKL-mediated osteoclast formation from murine RAW 264.7 cells.

Authors:  Patricia Collin-Osdoby; Philip Osdoby
Journal:  Methods Mol Biol       Date:  2012

2.  The anticancer activities of wogonin in murine sarcoma S180 both in vitro and in vivo.

Authors:  Wei Wang; Qing-Long Guo; Qi-Dong You; Kun Zhang; Yong Yang; Jun Yu; Wei Liu; Li Zhao; Hong-Yan Gu; Yang Hu; Zi Tan; Xiao-Tang Wang
Journal:  Biol Pharm Bull       Date:  2006-06       Impact factor: 2.233

Review 3.  Skeletal remodeling in health and disease.

Authors:  Mone Zaidi
Journal:  Nat Med       Date:  2007-07       Impact factor: 53.440

4.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

Authors:  Hiroshi Takayanagi; Sunhwa Kim; Takako Koga; Hiroshi Nishina; Masashi Isshiki; Hiroki Yoshida; Akio Saiura; Miho Isobe; Taeko Yokochi; Jun-ichiro Inoue; Erwin F Wagner; Tak W Mak; Tatsuhiko Kodama; Tadatsugu Taniguchi
Journal:  Dev Cell       Date:  2002-12       Impact factor: 12.270

Review 5.  Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells.

Authors:  Licheng He; Na Lu; Qinsheng Dai; Yue Zhao; Li Zhao; Hu Wang; Zhiyu Li; Qidong You; Qinglong Guo
Journal:  Toxicology       Date:  2013-07-30       Impact factor: 4.221

6.  Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis.

Authors:  Kabsun Kim; Jung Ha Kim; Junwon Lee; Hye-Mi Jin; Seoung-Hoon Lee; David E Fisher; Hyun Kook; Kyung Keun Kim; Yongwon Choi; Nacksung Kim
Journal:  J Biol Chem       Date:  2005-08-18       Impact factor: 5.157

7.  Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCgamma1- and Ca2+-dependent apoptosis.

Authors:  Sven Baumann; Stefanie C Fas; Marco Giaisi; Wolfgang W Müller; Anette Merling; Karsten Gülow; Lutz Edler; Peter H Krammer; Min Li-Weber
Journal:  Blood       Date:  2007-12-10       Impact factor: 22.113

8.  Wogonin induced differentiation and G1 phase arrest of human U-937 leukemia cells via PKCdelta phosphorylation.

Authors:  Hai-Wei Zhang; Yong Yang; Kun Zhang; Lei Qiang; Li Yang; Lan Yang; Yang Hu; Xiao-Tang Wang; Qi-Dong You; Qing-Long Guo
Journal:  Eur J Pharmacol       Date:  2008-06-12       Impact factor: 4.432

9.  Wogonin induces reactive oxygen species production and cell apoptosis in human glioma cancer cells.

Authors:  Cheng-Fang Tsai; Wei-Lan Yeh; Ssu Ming Huang; Tzu-Wei Tan; Dah-Yuu Lu
Journal:  Int J Mol Sci       Date:  2012-08-08       Impact factor: 6.208

10.  Wogonin has multiple anti-cancer effects by regulating c-Myc/SKP2/Fbw7α and HDAC1/HDAC2 pathways and inducing apoptosis in human lung adenocarcinoma cell line A549.

Authors:  Xin-mei Chen; Yang Bai; Yu-jian Zhong; Xiao-lin Xie; Han-wu Long; Yu-yin Yang; Shi-gen Wu; Qiang Jia; Xiao-hua Wang
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

View more
  2 in total

1.  Combined low-dose LiCl and LY294002 for the treatment of osteoporosis in ovariectomized rats.

Authors:  Jianhai Bai; Yier Xu; Yan Dieo; Guicai Sun
Journal:  J Orthop Surg Res       Date:  2019-06-13       Impact factor: 2.359

2.  GCTOF-MS Combined LC-QTRAP-MS/MS Reveals Metabolic Difference Between Osteoarthritis and Osteoporotic Osteoarthritis and the Intervention Effect of Erxian Decoction.

Authors:  Zhenyuan Ma; Yibao Wei; Li Zhang; Xiaoqing Shi; Runlin Xing; Taiyang Liao; Nan Yang; Xiaochen Li; Lishi Jie; Peimin Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-28       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.